Angiogenesis and prostate cancer tumor growth

Journal of Cellular Biochemistry

Volumn 91, Issue 1, 2004, Pages 125-150

  Nicholson, Brian ^a   Theodorescu, Dan ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Angiogenesis; Prostate cancer; VEGF

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENESIS INHIBITOR; CYCLOOXYGENASE 2; FIBROBLAST GROWTH FACTOR 2; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A;

ANGIOGENESIS; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR GROWTH; MALE; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; TUMOR SUPPRESSOR GENE; VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; CYCLOOXYGENASE 2; FIBROBLAST GROWTH FACTOR 2; GENES, TUMOR SUPPRESSOR; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3242806189     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.10772     Document Type: Review

References (190)

1. Abe J, Zhou W, Takuwa N, Taguchi J, Kurokawa K, Kumada M, Takuwa Y. 1994. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retino-blastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 54:3407-3412.
2. Akakura K, Suzuki H, Ueda T, Komiya A, Ichikawa T, Igarashi T, Ito H. 2003. Possible mechanism of dexamethasone therapy for prostate cancer: Suppression of circulating level of interleukin-6. Prostate 56:106-109.
3. Akiri G, Nahari D, Finkelstein Y, Le SY, Elroy-Stein O, Levi BZ. 1998. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 17:227-236.
4. Albelda SM, Muller WA, Buck CA, Newman PJ. 1991. Molecular and cellular properties of PECAM-1 (endoCAM/CD31): A novel vascular cell-cell adhesion molecule. J Cell Biol 114:1059-1068.
5. Arisawa C, Kageyama Y, Kawakami S, Kihara K. 2002. TNP-470 combined with nicardipine suppresses in vivo growth of PC-3, a human prostate cancer cell line. Urol Oncol 7:229-234.
6. Balbay MD, Pettaway CA, Kuniyasu H, Inoue K, Ramirez E, Li E, Fidler IJ, Dinney CP. 1999. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin Cancer Res 5:783-789.
7. Bauer KS, Figg WD, Hamilton JM, Jones EC, Premkumar A, Steinberg SM, Dyer V, Linehan WM, Pluda JM, Reed E. 1999. A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer. Clin Cancer Res 5:2324-2329.
8. Becker CM, Farnebo FA, Iordanescu I, Behonick DJ, Shih MC, Dunning P, Christofferson R, Mulligan RC, Taylor GA, Kuo CJ, Zetter BR. 2002. Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1. Cancer Biol Ther 1:548-553.
9. Billstrom A, Lecander I, Dagnaes-Hansen F, Dahllof B, Stenram U, Hartley-Asp B. 1995. Differential expression of uPA in an aggressive (DU 145) and a nonaggressive (1013L) human prostate cancer xenograft. Prostate 26: 94-104.
10. Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ. 2001. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A cancer and leukemia group B study. Cancer Res 61:2533-2536.
11. Borgstrom P, Bourdon MA, Hillan KJ, Sriramarao P, Ferrara N. 1998. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 35:1-10.
12. Borre M, Offersen BV, Nerstrom B, Overgaard J. 1998. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 78:940-944.
13. Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, Scardino PT, Humphrey PA, Hudson MA, Fradet Y, Miller GJ, Crawford ED, Blumenstein BA, Mahran HE, Miles BJ. 1996. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 48:47-57.
14. Brawer MK, Bigler SA, Deering RE. 1992. Quantitative morphometric analysis of the microcirculation in prostate carcinoma. J Cell Biochem Suppl 16H:62-64.
15. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. 1994. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 73:678-687.
16. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. 1994. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164.
17. Bulbul MA, Huben RP, Murphy GP. 1986. Interferon-beta treatment of metastatic prostate cancer. J Surg Oncol 33:231-233.
18. Campbell CL, Savarese DMF, Quesenberry PJ, Savarese TM. 1999. Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: Predominance of vascular endothelial growth factor. Int J Cancer 80:868-874.
19. Cao G, Su J, Lu W, Zhang F, Zhao G, Marteralli D, Dong Z. 2001. Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther 8:497-505.
20. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. 1999. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5:2674-2681.
21. Chen C, Parangi S, Tolentino MJ, Folkman J. 1995. A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res 55:4230-4233.
22. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. 1996. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271:736-741.
23. Connolly JM, Rose DP. 1998. Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice. J Urol 160:932-936.
24. Cvetkovic D, Movsas B, Dicker AP, Hanlon AL, Greenberg RE, Chapman JD, Hanks GE, Tricoli JV. 2001. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology 57:821-825.
25. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. 1994. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085.
26. de la Taille A, Katz AE, Bagiella E, Buttyan R, Sharir S, Olsson CA, Burchardt T, Ennis RD, Rubin MA. 2000. Microvessel density as a predictor of PSA recurrence after radical prostatectomy. A comparison of CD34 and CD31. Am J Clin Pathol 113:555-562.
27. Dembinska-Kiec A, Dulak J, Partyka L, Huk I, Mailnski T. 1997. VEGF-nitric oxide reciprocal regulation. Nat Med 3:1177.
28. Deroanne CF, Hajitou A, Calberg-Bacq CM, Nusgens BV, Lapiere CM. 1997. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res 57:5590-5597.
29. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Fidler IJ. 1998. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 58:808-814.
30. Dong Z, Greene G, Pettaway C, Dinney CP, Eue I, Lu W, Bucana CD, Balbay MD, Bielenberg D, Fidler IJ. 1999. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res 59:872-879.
31. Dong Z, Nemeth JA, Cher ML, Palmer KC, Bright RC, Fridman R. 2001. Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. Int J Cancer 93:507-515.
32. Drake MJ, Robson W; Mehta P, Schofield I, Neal DE, Leung HY. 2003. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 88:822-827.
33. Eastham JA, Truong LD, Rogers E, Rattan M, Flanders KC, Scardino PT, Thompson TC. 1995. Transforming growth factor-beta 1: Comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73:628-635.
34. Evans CP, Elfman F, Parangi S, Conn M, Cunha G, Shuman MA. 1997. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res 57:3594-3599.
35. Ezzell C. 1998. Starving tumors of their lifeblood. Sci Am 279:33-34.
36. Fairbrother WJ, Champe MA, Christinger HW, Keyt BA, Starovasnik MA. 1998. Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure 6:637-648.
37. Feng D, Nagy JA, Brekken RA, Pettersson A, Manseau EJ, Pyne K, Mulligan R, Thorpe PE, Dvorak HF, Dvorak AM. 2000. Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J Histochem Cytochem 48:545-556.
38. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL. 1997. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells [see comments]. J Urol 157:2329-23233.
39. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL. 1998. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51:161-167.
40. Festuccia C, Giunciuglio D, Guerra F, Villanova I, Angelucci A, Manduca P, Teti A, Albini A, Bologna M. 1999. Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion. Oncol Res 11:17-31.
41. Fidler IJ. 1995. Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 87:1588-1592.
42. Fidler IJ. 2001. Angiogenic heterogeneity: Regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst 93:1040-1041.
43. Fidler IJ, Naito S, Pathak S. 1990. Orthotopic implantation is essential for the selection, growth and metastasis of human renal cell cancer in nude mice [corrected]. Cancer Metastasis Rev 9:149-165.
44. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Kruger EA, Gubish E, Pluda JM, Reed E. 2001. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7:1888-1893.
45. Finkenzeller G, Marme D, Weich HA, Hug H. 1992. Platelet-derived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Cancer Res 52:4821-4823.
46. Folkman J. 1992. The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65-71.
47. Folkman J, Klagsbrun M. 1987. Angiogenic factors. Science 235:442-447.
48. Folkman J, Watson K, Ingber D, Hanahan D. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61.
49. Fortier AH, Nelson BJ, Grella DK, Holaday JW. 1999. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 91:1635-1640.
50. Fortier AH, Grella DK, Nelson BJ, Holaday JW. 2000. Response: Re: Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 92:345A-346.
51. Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI, Agus DB. 2002. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 8:3226-3231.
52. Galaup A, Opolon P, Bouquet C, Li H, Opolon D, Bissery MC, Tursz T, Perricaudet M, Griscelli F. 2003. Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model. Mol Ther 7:731-740.
53. Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, Schnaper HSV, Madison L, Volpert O, Bouck N, Enghild J, Kwaan HC, Soff GA. 1996. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 56:4887-4890.
54. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA. 1997. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 94:10868-10872.
55. Gaudric A, N'Guyen T, Moenner M, Glacet-Bernard A, Barritault D. 1992. Quantification of angiogenesis due to basic fibroblast growth factor in a modified rabbit corneal model. Ophthalmic Res 24:181-188.
56. Gettman MT, Bergstralh EJ, Blute M, Zincke H, Bostwick DG. 1998. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: Lack of significance for microvessel density analysis. Urology 51:79-85.
57. Gimbrone MA Jr, Leapman SB, Cotran RS, Folkman J. 1972. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136:261-276.
58. Gimbrone MA, Jr. Leapman SB, Cotran RS, Folkman J. 1973. Tumor angiogenesis: Iris neovascularization at a distance from experimental intraocular tumors. J Natl Cancer Inst 50:219-228.
59. Giraudo E, Primo L, Audero E, Gerber HP, Koolwijk P, Soker S, Klagsbrun M, Ferrara N, Bussolino F. 1998. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem 273:22128-22135.
60. Giri D, Ittmann M. 1999. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol 30:419-424.
61. Greene GF, Kitadai Y, Pettaway CA, von Eschenbach AC, Bucana CD, Fidler IJ. 1997. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 150:1571-1582.
62. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D. 1995. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 270:25915-25919.
63. Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS. 1999. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 59:1592-1598.
64. Guo Y, Jacobs SC, Kyprianou N. 1997. Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int J Cancer 71:573-579.
65. Hanahan D, Folkman J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
66. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K. 1996. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 74:910-916.
67. Hartley-Asp B, Vukanovic J, Joseph IB, Strandgarden K, Polacek J, Isaacs JT. 1997. Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer. J Urol 158:902-907.
68. Heidtmann HH, Nettelbeck DM, Mingels A, Jager R, Welker HG, Kontermann RE. 1999. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 81:1269-1273.
69. Hepburn PJ, Griffiths K, Harper ME. 1997. Angiogenic factors expressed by human prostatic cell lines: Effect on endothelial cell growth in vitro. Prostate 33:123-132.
70. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ. 1999. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-1998.
71. Hoosein NM, Boyd DD, Hollas WJ, Mazar A, Henkin J, Chung LW. 1991. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun 3:255-264.
72. Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E, Figg WD. 1999. Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. Br J Cancer 79:1588-1593.
73. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. 1991. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806-1814.
74. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. 1992. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031-26037.
75. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. 2000. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275:11397-11403.
76. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. 1997. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275:547-550.
77. Huang SF, Kim SJ, Lee AT, Karashima T, Bucana C, Kedar D, Sweeney P, Mian B, Fan D, Shepherd D, Fidler IJ, Dinney CP, Killion JJ. 2002. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. Cancer Res 62:5720-5726.
78. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. 2001. Angiogenesis and prostate cancer: Identification of a molecular progression switch. Cancer Res 61:2736-2743.
79. Ichikawa T, Lamb JC, Christensson PI, Hartley-Asp B, Isaacs JT. 1992. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res 52:3022-3028.
80. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP. 2000. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6:2104-2119.
81. Iughetti P, Suzuki O, Godoi PH, Alves VA, Sertie AL, Zorick T, Soares F, Camargo A, Moreira ES, di Loreto C, Moreira-Filho CA, Simpson A, Oliva G, Passos-Bueno MR. 2001. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 61:7375-7378.
82. Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ, Tilley WD. 2002. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 62:854-859.
83. Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F, Keshet E. 1998. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci USA 95:10820-10825.
84. Janvier R, Sourla A, Koutsilieris M, Doillon CJ. 1997. Stromal fibroblasts are required for PC-3 human prostate cancer cells to produce capillary-like formation of endothelial cells in a three-dimensional co-culture system. Anticancer Res 17:1551-1557.
85. Jiang Y, Muschel RJ. 2002. Regulation of matrix metalloproteinase-9 (MMP-9) by translational efficiency in murine prostate carcinoma cells. Cancer Res 62:1910-1914.
86. Jonca F, Ortega N, Gleizes PE, Bertrand N, Plouet J. 1997. Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor. J Biol Chem 272:24203-24209.
87. Joseph IB, Isaacs JT. 1997. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 57:1054-1057.
88. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. 1996. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:290-298.
89. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K. 1995. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 92:3566-3570.
90. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, Ferrara N. 1996. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 271:5638-5646.
91. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, Kato M, Oefelein MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C. 1996. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 2:1255-1261.
92. Kim SJ, Uehara H, Karashima T, McCarty M, Shih N, Fidler IJ. 2001. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 3:33-42.
93. Knox JD, Bretton L, Lynch T, Bowden GT, Nagle RB. 1998. Synthetic matrix metalloproteinase inhibitor, BB-94, inhibits the invasion of neoplastic human prostate cells in a mouse model. Prostate 35:248-254.
94. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM. 1992. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258:1798-1801.
95. Kollermann J, Helpap B. 2001. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am J Clin Pathol 116:115-121.
96. Konishi N, Hiasa Y, Tsuzuki T, Tao M, Enomoto T, Miller GJ. 1997. Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate 30: 53-57.
97. Krown SE. 1988. Interferons in malignancy: Biological products or biological response modifiers? J Natl Cancer Inst 80:306-309.
98. Krupski T, Petroni GR, Frierson HF Jr, Theodorescu JU. 2000. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology 55:743-749.
99. Krupski T, Harding MA, Herce ME, Guiding KM, Stoler MH, Theodorescu D. 2001. The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells. Growth Factors 18:287-302.
100. Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, Pettaway CA. 2000. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 6:2295-2308.
101. Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, Ingber D, Folkman J. 1994. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 69:212-216.
102. Lein M, Jung K, Le DK, Kasan T, Ortel B, Borchert D, Winkelmann B, Schnorr D, Loenings SA. 2000. Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth- in an orthotopic rat model. Prostate 43:77-82.
103. Lein M, Jung K, Ortel B, Stephan C, Rothaug W, Juchem R, Johannsen M, Deger S, Schnorr D, Loening S, Krell HW. 2002. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 21:2089-2096.
104. Lekas E, Johansson M, Widmark A, Bergh A, Damber JE. 1997. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 25:309-314.
105. Levy AP, Levy NS, Goldberg MA. 1996. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 271:2746-2753.
106. Li J, Perrella MA, Tsai JC, Yet SF, Hsieh CM, Yoshizumi M, Patterson C, Endege WO, Zhou F, Lee ME. 1995. Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells. J Biol Chem 270:308-312.
107. Linde N. 2001. NOVA: Cancer warrior: "NOVA." Alexandria, VA: PBS.
108. Liotta LA, Saidel MG, Kleinerman J. 1976. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 36:889-894.
109. Liotta LA, Steeg PS, Stetler-Stevenson WG. 1991. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64:327-336.
110. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. 2000. Tumor associated macrophages in human prostate cancer: Relation to clinico-pathological variables and survival. Int J Oncol 17:445-451.
111. Liu XH, Kirschenbaum A, Yao S, Stearns ME, Holland JF, Claffey K, Levine AC. 1999. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis 17:687-694.
112. Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU. 2001. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 7: 1198-1203.
113. Lokeshwar BL, Selzer MG, Block NL, Gunja-Smith Z. 1993. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: Reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 53:4493-4498.
114. Madaan S, Abel PD, Chaudhary KS, Hewitt R, Stott MA, Stamp GW, Lalani EN. 2000. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: Implications for prevention and treatment. BJU Int 86:736-741.
115. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. 1991. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88:9267-9271.
116. Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ. 1996. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 56:3436-3440.
117. Melnyk O, Zimmerman M, Kim KJ, Shuman M. 1999. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 161:960-963.
118. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, Kwon ED. 2001. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 98:14565-14570.
119. Mignatti P, Mazzieri R, Rifkin DB. 1991. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. J Cell Biol 113:1193-1201.
120. Morikawa W, Yamamoto K, Ishikawa S, Takemoto S, Ono M, Fukushi J, Naito S, Nozaki C, Iwanaga S, Kuwano M. 2000. Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells. J Biol Chem 275: 38912-38920.
121. Morton DM, Barrack ER. 1995. Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 55:2596-2602.
122. Muller YA, Christinger HW, Keyt BA, de Vos AM. 1997. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: Multiple copy flexibility and receptor binding. Structure 5:1325-1338.
123. Mustonen T, Alitalo K. 1995. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 129:895-898.
124. Nagakawa O, Murakami K, Yamaura T, Fujiuchi Y, Murata J, Fuse H, Saiki I. 2000. Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett 155:173-179.
125. Naito S, von Eschenbach AC, Giavazzi R, Fidler IJ. 1986. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 46:4109-4115.
126. Nakamoto T, Chang CS, Li AK, Chodak GW. 1992. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 52:571-577.
127. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D, Millar A. 1998. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 4:1101-1109.
128. Nicosia RF. 1998. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Pathol 153:11-16.
129. Noordzij MA, van der Kwast TH, van Steenbrugge GJ, Hop WJ, Schroder FH. 1995. The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 62:252-258.
130. O'Reilly MS, Holmgren L, Chen C, Folkman J. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689-692.
131. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. 1997. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285.
132. Offersen BV, Borre M, Overgaard J. 1998. Immunohistochemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer. APMIS 106:463-469.
133. Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M. 1998. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 273:31273-31282.
134. Paavonen K, Horelli-Kuitunen N, Chilov D, Kukk E, Pennanen S, Kallioniemi OP, Pajusola K, Olofsson B, Eriksson U, Joukov V, Palotie A, Alitalo K. 1996. Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively. Circulation 93:1079-1082.
135. Park JE, Keller GA, Ferrara N. 1993. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4:1317-1326.
136. Pasqualini R, Ruoslahti E. 1996. Organ targeting in vivo using phage display peptide libraries. Nature 380:364-366.
137. Pepper MS, Ferrara N, Orci L, Montesano R. 1992. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189:824-831.
138. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K. 1994. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 269:6271-6274.
139. Pu YS, Do KA, Luo W, Logothetis CJ, Lin SH. 2002. Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. Anticancer Drugs 13:743-749.
140. Rabbani SA. 1998. Metalloproteases and urokinase in angiogenesis and tumor progression. In Vivo 12:135-142.
141. Rabbani SA, Harakidas P, Davidson DJ, Henkin J, Mazar AP. 1995. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer 63:840-845.
142. Rak J, Mitsuhashi Y, Sheehan C, Tamir A, Viloria-Petit A, Filmus J, Mansour SJ, Ahn NG, Kerbel RS. 2000. Oncogenes and tumor angiogenesis: Differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 60:490-498.
143. Robinson CJ, Stringer SE. 2001. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114:853-865.
144. Ropiquet F, Giri D, Kwabi-Addo B, Mansukhani A, Ittmann M. 2000. Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. Cancer Res 60:4245-4250.
145. Rubin MA, Buyyounouski M, Bagiella E, Sharir S, Neugut A, Benson M, de la Taille A, Katz AE, Olsson CA, Ennis RD. 1999. Microvessel density in prostate cancer: Lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology 53:542-547.
146. Ruoslahti E. 2000. Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 10:435-442.
147. Saleh M, Stacker SA, Wilks AF. 1996. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56:393-401.
148. Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, Shapiro RL, Galloway AC, Rifkin DB, Mignatti P. 1998. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis. J Cell Biol 141:1659-1673.
149. Sehgal I, Thompson TC. 1999. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-betal in human prostate cancer cell lines. Mol Biol Cell 10:407-416.
150. Semenza GL, Wang GL. 1992. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12:5447-5454.
151. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985.
152. Senger DR, Perruzzi CA, Feder J, Dvorak HF. 1986. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46:5629-5632.
153. Sheta EA, Harding MA, Conaway MR, Theodorescu D. 2000. Focal adhesion kinase, Rap1, and transcriptional induction of vascular endothelial growth factor. J Natl Cancer Inst 92:1065-1073.
154. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. 2000. Reduced infiltration of tumor-associated macrophages in human prostate cancer: Association with cancer progression. Cancer Res 60: 5857-5861.
155. Sica G, Fabbroni L, Castagnetta L, Cacciatore M, Pavone-Macaluso M. 1989. Antiproliferative effect of interferons on human prostate carcinoma cell lines. Urol Res 17:111-115.
156. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. 1995. Interferons alpha and beta downregulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 92:4562-4566.
157. Smith PC, Keller ET. 2001. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 48:47-53.
158. Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A, Freeman MR. 2001. Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol 159:651-659.
159. Stearns ME. 1998. Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. Clin Exp Metastasis 16:332-339.
160. Stearns M, Wang M, Stearns ME. 1995. Cytokine (IL-10, IL-6) induction of tissue inhibitor of metalloproteinase 1 in primary human prostate tumor cell lines. Oncol Res 7:173-181.
161. Stearns ME, Fudge K, Garcia F, Wang M. 1997. IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression. Invasion Metastasis 17: 62-74.
162. Stearns ME, Garcia FU, Fudge K, Rhim J, Wang M. 1999a. Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 5:711-720.
163. Stearns ME, Rhim J, Wang M. 1999b. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 5:189-196.
164. Steiner MS, Zhou ZZ, Tonb DC, Barrack ER. 1994. Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology 135:2240-2247.
165. Steward WP. 1999. Marimastat (BB2516): Current status of development. Cancer Chemother Pharmacol 43(Suppl):S56-S60.
166. Stewart RJ, Panigrahy D, Flynn E, Folkman J. 2001. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 165:688-693.
167. Strohmeyer D, Rossing C, Bauerfeind A, Kaufmann O, Schlechte H, Bartsch G, Loening S. 2000. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 45:216-224.
168. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. 1994. Macrophages and angiogenesis. J Leukoc Biol 55:410-422.
169. Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP. 2002. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8:2714-2724.
170. Tang DG, Chen YQ, Newman PJ, Shi L, Gao X, Diglio CA, Honn KV. 1993. Identification of PECAM-1 in solid tumor cells and its potential involvement in tumor cell adhesion to endothelium. J Biol Chem 268:22883-22894.
171. Thalasila A, Poplin E, Shih J, Dvorzhinski D, Capanna T, Doyle-Lindrud S, Beers S, Goodin S, Rubin E, DiPaola RS. 2003. A phase I trial of weekly paclitaxel, 13-cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies. Cancer Chemother Pharmacol 52:119-124.
172. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. 1993. Association of transforming growth factor-beta 1 with prostate cancer: An immunohistochemical study. Hum Pathol 24:4-9.
173. Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR. 2002. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 62:6021-6025.
174. Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P. 2001. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 29:23-28.
175. Vukanovic J, Passaniti A, Hirata T, Traystman RJ, Hartley-Asp B, Isaacs JT. 1993. Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res 53: 1833-1837.
176. Walsh K, Sherwood RA, Dew TK, Mulvin D. 1999. Angiogenic peptides in prostatic disease. BJU Int 84: 1081-1083.
177. Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB. 1996. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 271:29483-29488.
178. Wartenberg M, Donmez F, Ling FC, Acker H, Hescheler J, Sauer H. 2001. Tumor-induced angiogenesis studied in confrontation cultures of multicellular tumor spheroids and embryoid bodies grown from pluripotent embryonic stem cells. FASEB J 15:995-1005.
179. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. 1993. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401-409.
180. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK, Durden DL. 2001. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 98:4622-4627.
181. Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. 1998. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37: 19-29.
182. Williams RH, Stapleton AM, Yang G, Truong LD, Rogers E, Timme TL, Wheeler TM, Scardino PT, Thompson TC. 1996. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: An immunohistochemical study. Clin Cancer Res 2:635-640.
183. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, Stearns ME. 1997. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 15:246-258.
184. Yamada Y, Nezu J, Shimane M, Hirata Y. 1997. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics 42:483-488.
185. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T. 1993. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 53:5233-5236.
186. Yokoyama Y, Green JE, Sukhatme VP, Ramakrishnan S. 2000. Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. Cancer Res 60:4362-4365.
187. Zhong H, Agani F, Baccala AA, Laughner E, Rioseco-Camacho N, Isaacs WB, Simons JW, Semenza GL. 1998. Increased expression of hypoxia inducible factor-1 alpha in rat and human prostate cancer. Cancer Res 58:5280-5284.
188. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. 1999. Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 59:5830-5835.
189. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL. 2000. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541-1545.
190. Zuck B, Goepfert C, Nedlin-Chittka A, Sohrt K, Voigt KD, Knabbe C. 1992. Regulation of fibroblast growth factor-like protein(s) in the androgen-responsive human prostate carcinoma cell line LNCaP. J Steroid Biochem Mol Biol 41:659-663.